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ABSTRACT 
Objective: A new method of cocrystallization based on the use of supercritical carbon dioxide (CO2) as an anti-solvent was explored. In the present study, we 
investigate and analyze paracetamol (PCA)-5-nitroisophthalic acid (5NIP) cocrystal produced using supercritical anti-solvent (SAS) process. 
Methods: PCA-5NIP cocrystals prepared by SAS cocrystallization were compared to those produced using traditional solvent evaporation by rapid 
evaporation (RE) process. The cocrystals produced were characterized using powder X-ray diffraction (PXRD), differential scanning calorimetry 
(DSC), thermogravimetric analysis (TGA), polarized light microscopy (PLM), Fourier Transform Infrared (FTIR) spectroscopy, particle size analysis 
and scanning electron microscopy (SEM). 
Results: The products obtained from SAS and RE process exhibited identical PXRD spectra and were distinguishable from the individual 
compounds, indicating the formation of a new phase. DSC analysis revealed that PCA-5NIP cocrystals from each method possess similar melting 
point which lies between the melting points of the parent compounds. Cocrystal particles with a mean diameter of 4.66 µm were produced from SAS 
process, which was smaller than those produced by traditional solvent evaporation method with a mean diameter of 38.09 μm.  
Conclusion: This study demonstrates the ability of SAS process to produce the submicron size of PCA-5NIP cocrystal with altered physicochemical 
properties in a single step process.  
Keywords: 5-nitroisophthalic acid, Carbon dioxide, Cocrystal, Paracetamol, Supercritical anti-solvent 




Pharmaceutical cocrystals have gained increasing popularity in the 
past decade due to their potentials in tuning various 
pharmaceutically relevant physicochemical properties such as 
solubility, permeability, bioavailability, hygroscopicity, mechanical 
properties and stability of active pharmaceutical ingredients (APIs) 
without compromising their pharmaceutical activity [1-7]. 
Pharmaceutical cocrystals also create new opportunities for 
pharmaceutical companies to address the intellectual property and 
new patent of APIs with regards to extend their life cycle [8]. A 
guidance and regulatory classification for pharmaceutical cocrystals 
has recently been released by European Medicines Agency (EMA) 
and United States Food and Drug Administration (FDA) [9, 10]. In 
the 2018 ‘Regulatory Classification of Pharmaceutical Co-Crystals: 
Guidance for Industry’, US FDA classified cocrystal as a crystalline 
material composed of two or more different molecules, typically 
APIs and cocrystal formers (“coformers”), in the same crystal lattice. 
According to the recent rules, cocrystal is considered as a drug 
polymorph rather than a new API and hence, the drug development 
and regulatory submissions are simplified [10]. 
Pharmaceutical cocrystals have been produced using several 
methods such as solution crystallization (e. g. solvent evaporation, 
slurry, cooling, antisolvent addition and reaction crystallization 
methods) [11-13] and mechanochemical approaches (e. g. neat and 
solvent drop grinding) [14, 15]. However, these traditional methods 
exhibited several disadvantages in cocrystals screening and scaling-
up process. Solution-based methods often require a large number of 
organic solvents which is environmentally undesirable. 
Furthermore, there is a risk of crystallization of the single-
component phase during crystallization process that may lead to 
partial or no cocrystal formation. In addition, remaining solvent 
residues may contaminate the product, and the production of 
mechanical stress and heat evolution during the grinding process 
can affect the thermal degradation of the components. Therefore, the 
development of novel and better methods for the screening and 
production of cocrystals is highly desirable [16-18]. 
Supercritical fluid (SCF)-based processes have also been used in 
cocrystal production as an alternative method. Several studies have 
previously been done in the production of pharmaceutical cocrystals 
using SCF techniques [19-24]. Carbon dioxide (CO2) at supercritical 
condition is mainly used due to its relatively low critical 
temperature (31.1 °C) and pressure (73.8 bar), nontoxic, 
nonflammable, environmentally benign and inexpensive [25]. The 
low solubility of many pharmaceutical compounds in supercritical 
CO2 makes CO2 anti-solvent an ideal technique for crystallization. 
Two of the most common CO2 anti-solvent techniques used for the 
crystallization of pharmaceuticals are supercritical anti-solvent 
(SAS) and gas anti-solvent (GAS). SAS technique is a single step 
process for simultaneous cocrystallization and micronization. This 
process is suitable for compounds that possess low solubility in SCF. 
In this process, a solution of an organic solvent is pumped through a 
nozzle into a chamber simultaneously with an SCF, which act as the 
anti-solvent. The particles are generated due to the supersaturation 
of solute within the solution droplet [26, 27]. Compared to 
traditional cocrystallization methods, SAS cocrystallization offers 
several advantages, which include a single step process and 
reduction of thermal and mechanical stress on API compared to 
grinding processes, and reduction of organic solvent uses and 
residual solvent content in cocrystal product compared to 
traditional solution-based method [28, 29]. In the previous work, we 
have successfully prepared pharmaceutical cocrystals between the 
drug paracetamol and coformer dipicolinic acid using SAS process 
[30]. In this work, we investigated the cocrystallization of 
paracetamol (PCA) and 5-nitroisophthalic acid (5NIP) by SAS 
process. The resulting cocrystal was analyzed and compared to 
cocrystal from traditional solvent evaporation process [5]. Solid-
state characterization techniques which include powder X-ray 
diffraction (PXRD), differential scanning calorimetry (DSC), fourier 
transform infrared (FTIR) spectroscopy, laser diffractometry (LD), 
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polarized light microscopy (PLM) and scanning electron microscopy 
(SEM) were performed for characterization.  
 
 
Fig. 1: Chemical structure of paracetamol (PCA) and 5-
nitroisophthalic acid (5NIP) 
 
MATERIALS AND METHODS 
Materials 
Paracetamol (PCA) was purchased from Zhejiang Kangle Pharmaceutical 
Co., Ltd. (Wenzhou, China). 5-Nitroisophthalic acid (5NIP) was obtained 
from Sigma-Aldrich, Co. (MO, USA). Methanol (ACS grade) was obtained 
from Merck KGaA (Darmstadt, Germany). High purity of carbon dioxide 
(CO2, purity of 99.95%) was purchased from PT Intergas (Jakarta, 
Indonesia). Polytetrafluoroethylene (PTFE) membrane with a size of 
0.22 μm was purchased from Fioroni Filters (Ingre, France). 
Cocrystallization by the rapid evaporation process 
Equimolar (1:1 mol ratio) quantities of PCA and 5NIP were dissolved 
in 20 ml of methanol and mixed under sonication at 40 °C for 10 
min. The resulting solution was then placed into a crystallizing disk 
and heated at 70 °C for 5 h using a hot plate to evaporate the solvent. 
The dried solid was collected and placed in the glass vial for further 
analysis. The cocrystal product obtained from this experiment was 
further mentioned as PCA-5NIP-RE. 
SAS cocrystallization apparatus 
Cocrystallization was conducted using a custom-built supercritical 
anti-solvent (SAS) apparatus as shown in fig. 2. Solution reservoir 
(9) was a 110 ml size Pyrex dropping funnel. High-pressure pump 
for CO2 (3) was a Thar P-50 pump (Thar Technology, PA, USA). High-
pressure pump for a solution (8) was a Lab Alliance 1200 series (Lab 
Alliance, PA, USA). The precipitation chamber (7) was made of 
stainless steel 316 (SS316) with 100 ml internal volume and water 
jacket to control the temperature of precipitator. To observe the 
process of particle formation, a pair of glass windows were installed 
in front and at the backside of precipitation chamber. A stainless 
steel capillary tube with internal diameter of 2.54 x 10-4 m was used 
as a nozzle and it was placed on the top of precipitation chamber. 
The CO2 precooler (2) and preheater (6) were a shell and tube type, 
respectively. The inner tube was a coiled tube with 0.6 m length and 
3.175 x 10-3 m outside diameter that made of SS316. The shell was 
made from SS316 with 0.11 m diameter and 0.25 m length. The 
products were filtered using 0.22 µm polytetrafluoroethylene 
(PTFE) membrane filter (10). Pressure of the precipitation chamber 
was controlled using a model 26-1721-24 back pressure regulator 
(11) manufactured by Tescom, Co. (MN, USA). The precooler and CO2 
pump temperature were maintained using a cooling circulator (4). 
SAS cocrystallization 
Equimolar (1:1 mol ratio) quantities of PCA and 5NIP were dissolved 
in 20 ml of methanol and mixed under sonication at 40 °C for 10 min 
to obtain clear solution. The cocrystallization started by supplying 
fresh CO2 into the precipitation chamber. After stable pressure (100 
bar) and temperature (40 °C) was achieved, solution was sprayed 
into precipitation chamber at a flow rate of 1 ml/min and CO2 was 
pumped into the precipitation chamber at the same time at a CO2 
flow rate of 30 g/min. After solutions have been sprayed, CO2 was 
continuously supplied for 30 min to remove the remaining solvent in 
the product inside the precipitation chamber and filter. Products 
were collected from the filter after depressurizing the precipitation 
chamber. The cocrystal product obtained from this experiment was 
further mentioned as PCA-5NIP-SAS. 
Powder X-ray diffraction (PXRD)  
Powder X-ray diffraction (PXRD) patterns were collected by Rigaku 
Ultima IV X-ray diffractometer (Rigaku Co., Tokyo, Japan) using Cu 
Kα radiation (λ = 1.54 Å), a tube voltage of 40 kV and a tube current 
of 40 mA. Data were collected from 2 to 40 ° at a continuous scan 
rate of 4 °/min. 
Differential scanning calorimetry (DSC) 
Thermal analysis of the samples was performed using differential 
scanning calorimetry (DSC) on DSC Q20 (TA Instruments, DE, USA) 
which was calibrated for temperature and cell constants using 
indium. Samples (1-3 mg) crimped in the aluminum pan were 
analyzed from 50 to 300 °C with a heating rate of 10 °C/min. 
Samples were continuously purged with nitrogen at 50 ml/min. 
Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was performed on a TGA Q50 
(TA Instruments, DE, USA) instrument. Approximately 1-5 mg 
sample was heated from 50 to 300 °C in an open aluminum pan at a 
rate of 10 °C/min under nitrogen purge at a flow rate of 50 ml/min. 
Polarized light microscopy (PLM) 
Polarized light microscopy (PLM) experiments were performed 
using BX-50 polarizing microscope (Olympus, Tokyo, Japan). 
Photomicrographs were captured using an Olympus SC-30 digital 
color camera and analyzed using AnalySIS getIT software. 
Fourier transform infrared (FTIR) spectroscopy 
IR spectra of the compounds were recorded on an FT/IR-6100 type 
A infrared spectrometer (JASCO, MD, USA) in ATR mode from 4000-
700 cm-1 with a resolution of 4 cm-1. 
Particle size analysis 
Particle size was determined by a laser diffractometer (Mastersizer 
2000, Malvern Instruments, USA) using the dry powder dispersing 
system Scirocco 2000 at 2 bar pressure. Particle size was 
characterized by volume-weighted mean diameter D [4,3]. The 
particle size results represent the average values over three 
measurements performed on each sample. 
Scanning electron microscopy (SEM) 
Morphology of the samples was analyzed using a JEOL JSM-6510 
scanning electron microscopy (SEM, JEOL Ltd. Tokyo, Japan). 
Samples were mounted on a double-faced adhesive tape, sputtered 
with platinum. Scanning electron photographs were taken at an 
accelerating voltage of 5 kV. 
 
 
Fig. 2: Schematic diagram of custom-built SAS apparatus: (1) CO2 
cylinder, (2) precooler, (3) high-pressure pump for CO2, (4) cooling 
bath, (5) heating bath, (6) preheater, (7) precipitation chamber, (8) 
high-pressure pump for solution, (9) solution reservoir, (10) filter, 
(11) back pressure regulator, (12) separator 
Tjandrawinata et al. 
Int J App Pharm, Vol 11, Issue 5, 2019, 194-199 
196 
RESULTS AND DISCUSSION 
Powder X-ray diffraction (PXRD) analysis 
PXRD analysis was used to identify the formation of novel crystalline 
phase in solid-state. Every crystalline phase of a compound 
exhibited its own characteristic PXRD pattern, thus PXRD has 
commonly been used to distinguish the resulting products from the 
starting materials [5]. The PXRD patterns for PCA, 5NIP and PCA-
5NIP physical mixture are shown in fig. 3a-c. PCA exhibited 
characteristic crystalline peaks at 2θ values of 12.80°, 15.50°, 18.12°, 
21.96°, 23.46°, 24.34° and 26.50°, whereas 5NIP exhibited 
characteristic crystalline peaks at 2θ values of 18.00°, 20.40°, 21.14°, 
23.48° and 28.60°. Fig. 3d-e shows PXRD patterns of the products 
obtained from cocrystallization process via rapid solvent 
evaporation and SAS. The products obtained from each method 
exhibited identical spectra, and the diffractogram of PCA-5NIP 
cocrystal was distinguishable from the individual compounds. The 
different peaks in PXRD pattern of the cocrystal could imply the 
existence of interactions between PCA and 5NIP to form a new 
crystalline phase. This PXRD result also confirms that PCA-5NIP 
cocrystal was successfully produced from SAS cocrystallization 
experiment and exhibited similar internal crystal structure with 
PCA-5NIP cocrystal from rapid solvent evaporation process. As 
shown in fig. 3d-e, the intensity of the diffraction peaks were 
different at several 2θ positions, although the characteristic 
diffraction peaks from PCA-5NIP-RE and PCA-5NIP-SAS cocrystals 
were observed at the same 2θ position.  
The difference of diffraction peaks intensity can be explained by the 
preferred orientation, which is a condition in which the distribution 
of crystal orientation is non-random and a specific crystalline frame 
may tend to cluster to a greater or lesser degree about some 
particular orientations [31]. These results showed that 
crystallization condition may control the crystallinity of the product. 
 
 




DSC and TGA experiments were carried out to study the thermal 
behavior of PCA-5NIP cocrystals. DSC thermograph of PCA, 5NIP, 
physical mixture of PCA and 5NIP at 1:1 mol ratio, PCA-5NIP-RE and 
PCA-5NIP-SAS are shown in fig. 4. It shows that PCA exhibited a 
melting endothermic peak at 170.23 °C, while 5NIP showed a 
melting endothermic at 260.28 °C. DSC analysis of the physical 
mixture of PCA and 5NIP showed 4 endothermic peaks (fig. 4c). First 
endothermic peak at 148.66 °C could be attributed to the eutectic 
temperature of PCA and 5NIP mixture, and second melting 
endotherm at 162.69 °C was indicated as cocrystal eutectic melting 
with an excess of high-melting component. The third peak at 204.11 
°C indicates the melting point of the cocrystal followed by 
decomposition of cocrystal, as confirmed by TGA result. This 
observation was in accordance to the report by Lu et al. which 
demonstrated that DSC can be used for cocrystal screening [32]. 
They explained that the formation of cocrystal could be predicted if 
there were two endothermic peaks (corresponding to eutectic 
mixture and cocrystal melting) obtained during the physical mixture 
melting process in DSC analysis. DSC analysis of the products from 
cocrystallization experiments showed single endothermic peak 
which lies between the melting points of the parent compounds. 
PCA-5NIP-RE and PCA-5NIP-SAS exhibited endothermic melting 
point at 205.28 °C and 203.93 °C, respectively. A statistical study by 
Perlovich on 727 cocrystal systems indicated that the majority of 
cocrystals (55.3%) exhibited melting points in between those of the 
drug and coformer, while 15.8% of cocrystals possessed higher 
melting point and 28.9% showed lower melting point than those of 
the individual compounds [33]. The shift in the melting point of PCA-
5NIP cocrystal might be attributable to the interaction between PCA 
and 5NIP, which altered the change in the crystal lattice and formed 
a relatively different internal crystal structure of PCA-5NIP cocrystal 
[34]. The enthalpy of fusion, ∆H of PCA-5NIP-RE and PCA-5NIP-SAS 
were 192.0 and 94.93 J/g, respectively, which showed that cocrystal 
from SAS cocrystallization possesses lower enthalpy of fusion. The 
lower enthalpy of fusion of PCA-5NIP cocrystal from SAS process 
might possibly due to the reduction of particle size or lowered 
crystalinity following SAS process [25, 35]. 
TGA was conducted to analyze the changes in cocrystal weight with 
regards to the change of temperature (fig. 5). TGA curve showed no 
weight loss until melting, suggesting that PCA-5NIP-RE and PCA-
5NIP-SAS cocrystals were not solvated or hydrated. TGA of these 
cocrystals showed the occurrence of mass loss after melting points, 
which attributed to the degradation of cocrystals. 
 
 
Fig. 4: DSC thermograms of (a) PCA, (b) 5NIP, (c) physical 
mixture of PCA: 5NIP (1:1 mol ratio), (d) PCA-5NIP-RE and (e) 
PCA-5NIP-SAS
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Fig. 5: TGA thermograms of PCA, 5NIP, PCA-5NIP-RE and PCA-5NIP-SAS 
 
Fourier transform infrared (FTIR) spectroscopy 
FTIR spectroscopy can be used to confirm cocrystal formation by 
evaluating the changes in vibrational frequencies of specific 
functional groups of the product compared to their starting 
components [36]. Based on the chemical structures of PCA and 5NIP 
(fig. 1), there are several functional groups that are able to form 
intermolecular hydrogen bonding, and thus several possible 
synthons to form can be obtained. The FTIR spectra of PCA, 5NIP, 
PCA-5NIP-RE and PCA-5NIP-SAS cocrystal are shown in fig. 6. FTIR 
spectra of PCA-5NIP cocrystal showed several different 
wavenumbers for several major bands compared to their individual 
components. The new bands at 3446.42 cm-1 in PCA-5NIP-RE 
cocrystals and 3465.46 cm-1 in PCA-5NIP-SAS cocrystals can be 
assigned to the intermolecular hydrogen bond interaction between 
O carboxylic acid and N-H amide (O∙∙∙N-H) [37, 38]. The shift in 
spectral peaks has also been observed for the carbonyl functional 




Fig. 6: FTIR spectra of (a) PCA, (b) 5NIP, (c) PCA-5NIP-RE and (d) PCA-5NIP-SAS 
 
Polarized light microscope (PLM) images 
Fig. 7 shows PLM photomicrographs of PCA, 5NIP and physical 
mixture of PCA and 5NIP (1:1 mol ratio) after recrystallization from 
methanol. It showed that recrystallization of PCA and 5NIP (1:1 mol 
ratio) physical mixture produced different crystal habit compared to 
the crystal habit of its starting components (PCA and 5NIP). Although 
in general, the different crystal habit between crystallization product 
and its starting components was not a proof to the formation of a new 
crystalline phase, this phenomena may provide a preliminary 
information about the possible interaction of the starting components 
to produce a new crystalline phase (cocrystal). In this study, the 
interaction between PCA and 5NIP produced a new crystalline phase 
as confirmed by PXRD, DSC and FTIR analysis, and thus we conclude 
that the different crystal habit was generated due to the interaction 
between PCA and 5NIP to form a new crystalline phase. Crystal habit 
of a drug is an important variable in pharmaceutical manufacturing. 
The changes in the crystal habit of a raw material after 
cocrystallization may influence its physico-mechanical properties and 
affect the performance of the dosage form [39]. 
Scanning electron microscope (SEM) and laser diffractometer 
(LD) analysis 
Fig. 8 shows SEM micrographs of PCA, 5NIP, and PCA-5NIP 
cocrystal. PCA and 5NIP crystals exhibited an irregular rod-like or 
columnar habit, whereas PCA-5NIP-RE and PCA-5NIP-SAS 
cocrystal showed thin plate-like crystals. SEM micrographs of the 
cocrystal clearly show that the crystal habit of PCA-5NIP cocrystal 
was different compared to its individual components. SEM image 
also revealed that cocrystal from SAS process showed a smaller 
particle size compared to those produced from the rapid 
evaporation process. Crystal habit of the API is an important 
parameter in pharmaceutical processing, since it influences 
various pharmaceutical parameters such as flow properties and 
compaction characteristic of drug powder [39]. The particle size 
distribution (PSD) patterns from LD analysis illustrated in fig. 9 
show that SAS process can produce PCA-5NIP cocrystal with 
smaller average particle size and narrower PSD. This result 
indicates that SAS process is an efficient process to produce sub-
micron size of PCA-5NIP cocrystal. 
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Fig. 7: Polarized light microscopy (PLM) images of PCA, 5NIP and physical mixture of PCA: 5NIP (1:1 mol ratio) after recrystallization 
using methanol (PM) 
 
 
Fig. 8: SEM images of PCA, 5NIP, PCA-5NIP-RE and PCA-5NIP-SAS 
 
 
Fig. 9: Particle size distribution (PSD) profile of PCA, PCA-5NIP-RE and PCA-5NIP-SAS 
 
CONCLUSION 
In summary, cocrystals of PCA and 5NIP were successfully prepared 
using supercritical anti-solvent (SAS) process. The formation of new 
crystalline phases was confirmed by PXRD, DSC, FTIR, PLM, SEM and 
LD analysis. Particle size of cocrystal particles produced by SAS was 
smaller than those produced by traditional rapid solvent 
evaporation process. This study demonstrates the ability of SAS 
process to produce the sub-micron size of PCA-5NIP cocrystal with 
altered physicochemical properties in a single step process.  
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